BioCentury
ARTICLE | Clinical News

Idorsia insomnia candidate headed for Phase III

July 28, 2017 11:04 PM UTC

Idorsia Ltd. (SIX:IDIA) said ACT-541468 led to a significant, dose-dependent reduction in Wake After Sleep Onset (WASO) from baseline on the first two nights of treatment in a pair of Phase II trials to treat insomnia, meeting the primary endpoint in both trials.

The company plans to consult with regulatory authorities and move the candidate into Phase III testing "as quickly as possible." ACT-541468 is a dual orexin receptor antagonist...

BCIQ Company Profiles

Idorsia Ltd.